How to access Wainzua from Saudi Arabia — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Wainzua (eplontersen) from their treating neurologist in a tertiary centre in Riyadh, Jeddah, or the Eastern Province. Wainzua is FDA-approved for this indication and developed by Ionis Pharmaceuticals in partnership with AstraZeneca. In Saudi Arabia, Wainzua is not routinely registered for outpatient dispensing for this indication, and access is typically coordinated through the named-patient import pathway.
This guide explains the legal pathway, documentation your neurologist prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Wainzua is a ligand-conjugated antisense oligonucleotide (LICA-ASO) that silences hepatic TTR production, administered subcutaneously once monthly via auto-injector. Eligibility requires genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy, and workup to characterise any cardiac amyloidosis overlap. Your neurologist will establish baseline neuropathy impairment score, mNIS+7, polyneuropathy disability score, and quality-of-life measures. Wainzua's self-administration profile is a meaningful convenience advantage — patients can self-inject at home after clinic training.
Is Wainzua legally importable into Saudi Arabia?
Yes — through the Saudi Food and Drug Authority (SFDA) named-patient / special-access import framework. The mechanism permits a KSA-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented. hATTR polyneuropathy has limited disease-specific registered options on Saudi formularies, which simplifies clinical rationale.
How the pathway works, step by step
- Consultation with your treating neurologist. TTR genetic report, neuropathy scoring, and clinical rationale.
- Baseline assessment. mNIS+7, polyneuropathy disability score, cardiac workup (ECG, echocardiogram, NT-proBNP).
- SFDA named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing schedule, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Wainzua from authorised distribution under DSCSA.
- Cold-chain shipment. Wainzua requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging.
- Arrival and dispensing. The hospital pharmacy releases the auto-injector to the patient after clinic-based self-administration training.
What documentation your physician needs
- Clinical rationale letter confirming hATTR polyneuropathy and Wainzua as the indicated therapy
- Verification of Saudi medical license (SCFHS)
- TTR genetic test result
- Baseline mNIS+7 and polyneuropathy disability score
- Cardiac assessment for ATTR-CM overlap
- Planned monthly dosing schedule and monitoring plan
Reserve Meds provides a physician documentation kit bundling templates SFDA reviewers expect for rare-disease neurology named-patient imports.
Costs and timing
Wainzua's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 440,000–470,000 (dosed monthly). International logistics, SFDA documentation handling, cold-chain shipment, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete SFDA application is submitted.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and SFDA review.
- Logistics. Validated cold-chain shipment to your prescribing hospital pharmacy.
- Concierge case lead. A named point of contact coordinating monthly refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist. We operate on a waitlist basis during pre-launch.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. See our trust and compliance page.
How is Wainzua different from Amvuttra or Onpattro? All three silence hepatic TTR but differ in chemistry and administration — Wainzua is subcutaneous antisense (monthly, auto-injector), Amvuttra is subcutaneous siRNA (quarterly), Onpattro is intravenous siRNA (every three weeks). Your neurologist selects based on clinical picture and patient preference.
Can I self-inject at home? Yes, after clinic-based training on the auto-injector, consistent with FDA labeling.
Will insurance cover this? Cash-pay is the default. Some Saudi private insurers consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Wainzua coordination.
Add me to the Wainzua waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.